Eli Lilly and Co.

Description goes here

ARTICLES

UPDATE: Lilly says it couldn't have made tainted Cialis

A batch of Cialis pills, purportedly made at a plant in Australia, was banned by the FDA from entering the U.S. after the pills were found to contain the active ingredient for rival drug Viagra. Cialis manufacturer Eli Lilly said it doesn't make any drugs in Australia.
Read More

Lilly sees insurers pushing harder for discounts

Health-coverage managers are becoming more aggressive in demanding discounts and exclusive deals from drugmakers to drive down the cost of medicine, Eli Lilly and Co.’s diabetes business chief says.
Read More

UPDATE: Lilly forecasts earnings below analyst expectations

The Indianapolis-based drugmaker said its long-term strategy is on track, but predicted sales this year would be $20.3 billion to $20.8 billion, a shade below what Wall Street was expecting.
Read More

Lilly to sell heartworm line for Novartis deal approval

Eli Lilly and Co. wants to combine Novartis with its own animal health business, Elanco, to create the second-largest animal health company in the U.S.
Read More

Lilly reaches insulin development deal with Adocia

Eli Lilly and Co. could pay more than $570 million to French pharmaceutical company Adocia under an agreement to develop a fast-acting insulin that is in the early stages of clinical testing.
Read More

Lilly bumps up dividend for first time since 2009

Shares of Eli Lilly and Co. were on the rise Tuesday morning, a day after the drugmaker announced its first dividend increase in more than five years.
Read More

Lilly's Cyramza gets new marketing approval

Eli Lilly and Co.'s drug Cyramza has been approved as a treatment for lung cancer, regulators said. The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread.
Read More

Alzheimer’s tests present dilemma of knowing the future

While the tests will likely help drug companies like Eli Lilly and Co. evaluate medicines, they’ll also create wrenching personal and ethical dilemmas for patients who will have to live with the knowledge that they’re destined to develop the disease.
Read More

Covance shareholder sues over $6.1B LabCorp deal

A Covance Inc. investor contends in a lawsuit that the drug-testing company’s board erred in relying on what the shareholder called Goldman Sachs Group Inc.’s conflict-tainted advice. Covance has major laboratory operations in Indianapolis.
Read More

Lilly rheumatoid arthritis drug meets goals in final-stage trial

If approved, Baricitinib may bring Lilly $673 million in 2020, according to the average of five analysts’ estimates compiled by Bloomberg.
Read More